What LEADER Actually Changes in Clinical Practice

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for What LEADER Actually Changes in Clinical Practice

At a glance

  • Trial name: LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results)
  • N: 9,340 patients
  • Intervention: Liraglutide 1.8 mg subcutaneous daily
  • Comparator: Matching placebo (both added to standard of care)
  • Duration: Median 3.8 years follow-up
  • Primary endpoint: First occurrence of 3-point MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke)
  • Key result: HR 0.87 (95% CI 0.78, 0.97; p = 0.01 for superiority), primary publication

Why LEADER Mattered More Than Its Headline

Before LEADER reported in June 2016, the FDA had required cardiovascular outcomes trials (CVOTs) for all new diabetes drugs since 2008. The bar was low: prove your drug does not increase cardiovascular risk. Several DPP-4 inhibitors had cleared that bar with neutral results. LEADER was the first GLP-1 receptor agonist CVOT to cross from noninferiority into outright superiority, meaning liraglutide did not simply avoid harm but actively reduced events.

That distinction matters for prescribing. A drug that is "not worse" than placebo for the heart does not earn preferential placement. A drug that prevents heart attacks and cardiovascular death in a high-risk population does.

Trial Design: What the Abstract Leaves Out

LEADER randomized patients 1:1 across 410 sites in 32 countries. Eligibility required type 2 diabetes with HbA1c ≥7.0% plus either established cardiovascular disease (age ≥50) or cardiovascular risk factors (age ≥60). Roughly 81% of enrollees had established cardiovascular disease at baseline, which skews the population toward secondary prevention.

A few design details deserve attention:

Open-label glycemic management. Investigators could adjust all background diabetes medications except other GLP-1 receptor agonists, DPP-4 inhibitors, or pramlintide. This means the placebo group was not undertreated. They received intensified standard care, including insulin titration, making the cardiovascular benefit attributable to liraglutide itself rather than better glucose control in the active arm.

Dose target. The protocol targeted 1.8 mg daily, the maximum approved dose. About 77% of participants in the liraglutide group reached and stayed at 1.8 mg. The trial does not answer whether 1.2 mg (a common real-world dose) provides the same cardiovascular protection.

Event-driven design. The trial continued until at least 611 primary endpoint events had accrued and all patients had been followed for a minimum of 42 months. This is important because it gave sufficient statistical power to test superiority after noninferiority was confirmed, a hierarchical testing approach detailed in the protocol.

Results in Detail

Primary and Secondary Endpoints

| Endpoint | Liraglutide | Placebo | HR (95% CI) | p-value | |---|---|---|---|---| | 3-point MACE (primary) | 13.0% | 14.9% | 0.87 (0.78, 0.97) | 0.01 | | Cardiovascular death | 4.7% | 6.0% | 0.78 (0.66, 0.93) | 0.007 | | Nonfatal MI | 6.0% | 6.8% | 0.88 (0.75, 1.03) | 0.11 | | Nonfatal stroke | 3.4% | 3.1% | 1.11 (0.88, 1.39) | 0.40 | | All-cause mortality | 8.2% | 9.6% | 0.85 (0.74, 0.97) | 0.02 | | Hospitalization for heart failure | 4.7% | 5.3% | 0.87 (0.73, 1.05) | 0.14 |

The MACE reduction was driven primarily by cardiovascular death (HR 0.78), not by MI or stroke individually. All-cause mortality was also significantly lower with liraglutide (HR 0.85). This is a hard endpoint that is difficult to attribute to bias or ascertainment differences.

Subgroup Signals Worth Noting

Prespecified subgroup analyses showed consistent benefit across most categories, but two patterns stood out. Patients with established cardiovascular disease (the 81% majority) showed a stronger signal than those enrolled on risk factors alone. And patients with eGFR <60 mL/min appeared to derive at least as much benefit, which matters because renal impairment is common in this population and clinicians sometimes hesitate to prescribe GLP-1 agents in kidney disease.

Glycemic and Metabolic Effects

HbA1c fell by an additional 0.40 percentage points with liraglutide versus placebo at 36 months. Body weight decreased by 2.3 kg more with liraglutide. Systolic blood pressure dropped by 1.2 mmHg more. These are modest metabolic differences that almost certainly do not explain a 22% reduction in cardiovascular death on their own, suggesting mechanisms beyond glucose lowering.

What Changed in Guidelines After LEADER

LEADER, together with the EMPA-REG OUTCOME trial for empagliflozin, triggered the most significant restructuring of diabetes treatment algorithms in a decade.

ADA/EASD 2018 Consensus Report. Before these CVOTs, metformin was first-line and second-line choice was based on cost, side effects, and HbA1c potency. The 2018 ADA/EASD consensus changed the decision tree: for patients with established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit (liraglutide specifically cited) or an SGLT2 inhibitor with proven benefit should be preferred as add-on to metformin, regardless of HbA1c level.

ADA Standards of Care (2020 onward). Subsequent annual updates have strengthened this position. By 2023, ADA guidance recommended considering GLP-1 receptor agonists with proven cardiovascular benefit even before metformin in patients with established cardiovascular disease or high cardiovascular risk, removing the traditional metformin-first requirement in this subgroup.

ACC/AHA alignment. Cardiology societies incorporated these agents into secondary prevention frameworks, a significant shift because cardiologists, not just endocrinologists, began initiating GLP-1 prescriptions.

What LEADER Does Not Tell You

1. The trial population is narrower than real-world prescribing

The mean age was 64. Mean diabetes duration was 12.8 years. Over 80% had established cardiovascular disease. Mean BMI was 32.5. This is a specific phenotype: older patients with longstanding diabetes and known vascular disease. LEADER does not prove cardiovascular benefit in younger patients with newly diagnosed type 2 diabetes and no cardiovascular history. Clinicians sometimes extrapolate LEADER to justify liraglutide for a 45-year-old with prediabetes. That extrapolation is not supported by the data.

2. The dose question remains open

Most real-world prescribing data shows that a substantial fraction of patients take liraglutide at 1.2 mg due to gastrointestinal side effects. LEADER tested 1.8 mg. Whether the cardiovascular benefit persists at the lower dose is unknown. The FDA label for Victoza includes the cardiovascular indication at 1.8 mg.

3. Mechanism of benefit is still debated

LEADER was not designed to explain how liraglutide reduces cardiovascular death. Proposed mechanisms include direct effects on atherosclerosis, improvements in endothelial function, anti-inflammatory properties, and modest reductions in blood pressure and weight. No single mechanism has been confirmed, and the benefit emerged relatively early (Kaplan-Meier curves began separating by 12 to 18 months), which argues against slow atherosclerotic plaque regression as the primary driver.

4. No head-to-head data against semaglutide at the time

The SUSTAIN-6 trial for semaglutide (reported the same year) showed a 26% MACE reduction, numerically larger than LEADER's 13%. But these trials had different populations, different follow-up durations, and different event rates. Direct comparison is unreliable. The later SELECT trial tested semaglutide in obesity without diabetes, a different question entirely.

How This Should Change Prescribing Today

For patients with type 2 diabetes and established atherosclerotic cardiovascular disease: A GLP-1 receptor agonist with proven cardiovascular benefit should be part of the regimen unless contraindicated. LEADER established this principle. The choice between liraglutide and newer agents like semaglutide depends on formulary access, cost, and injection frequency preference (daily versus weekly).

For patients with type 2 diabetes and cardiovascular risk factors but no established disease: The evidence is weaker. LEADER's subgroup analysis suggests less clear benefit in this population, and guidelines appropriately use softer language ("consider" rather than "recommend").

For clinicians still defaulting to sulfonylureas or basal insulin as second-line: LEADER (and subsequent CVOTs) eliminated the clinical rationale for choosing a sulfonylurea over a GLP-1 receptor agonist in a patient with cardiovascular risk, assuming insurance coverage allows it. Sulfonylureas have never demonstrated cardiovascular benefit in a modern CVOT.

For cardiologists: LEADER created a new prescribing responsibility. If a patient presents with an MI and has type 2 diabetes, initiating or recommending a GLP-1 receptor agonist with cardiovascular benefit is now within cardiology's scope, similar to how statins became a cardiology-initiated medication decades ago.

The LEADER Legacy in Context

LEADER was not the last word. SUSTAIN-6, HARMONY Outcomes (albiglutide), REWIND (dulaglutide), and SELECT (semaglutide 2.4 mg) have all contributed to the evidence base for GLP-1 receptor agonists and cardiovascular or cardiometabolic outcomes. But LEADER was the proof of concept. It demonstrated that a GLP-1 receptor agonist could do more than lower glucose safely. It could prevent cardiovascular death. That single finding restructured how diabetes and cardiovascular disease are treated together.

The trial's limitations are real. Its population was old, sick, and predominantly white (77%). Its dose was higher than many patients tolerate. Its mechanism remains uncertain. But its core finding, a statistically significant reduction in cardiovascular death with a diabetes drug, changed the standard of care permanently.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Marso SP, Daniels GH, Poulter NR, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. PubMed
  2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. PubMed
  3. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the ADA and EASD. Diabetes Care. 2018;41(12):2669-2701. PubMed
  4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. PubMed
  5. Victoza (liraglutide) prescribing information. U.S. Food and Drug Administration. FDA Label